Screener
Agios Pharmaceuticals AGIO Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | $2,996 | $1,702 | $4,315 | $2,787 |
| Research and development | 100,754 | 91,940 | 181,902 | 164,683 |
| Selling, general and administrative | 51,547 | 45,869 | 99,851 | 87,396 |
| Total operating expenses | 155,297 | 139,511 | 286,068 | 254,866 |
| Loss from operations | (110,552) | (127,056) | (220,577) | (233,685) |
| Interest income, net | 9,730 | 14,513 | 20,525 | 30,600 |
| Other income, net | 119 | 523 | 238 | 1,776 |
| Net loss | $(100,703) | $(112,020) | $(199,814) | $(201,309) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's total costs & expenses?
- Agios Pharmaceuticals (AGIO) reported total costs & expenses of $155.3M in Q2 2026.
- How has Agios Pharmaceuticals's total costs & expenses changed year-over-year?
- Agios Pharmaceuticals's total costs & expenses increased by 11.3% year-over-year, from $139.51M to $155.3M.
- What is the long-term trend for Agios Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's total costs & expenses has grown at a 8.6% compound annual growth rate (CAGR), from $378.42M to $526.16M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating and non-operating costs incurred by the company during a reporting period, including research and development, selling, general, and administrative expenses. It serves as a comprehensive measure of the total capital outflow required to sustain business operations and advance the clinical development pipeline. Monitoring this figure is essential for assessing the company's overall cost structure and operational efficiency relative to its revenue generation.
Ask your AI about Agios Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude